Navigation Links
Study shows pine bark naturally improves kidney function in patients with metabolic syndrome
Date:3/1/2011

ths of treatment. Pycnogenol also led to a remarkable improvement of blood flow velocity of the kidney arteries. Blood flow velocity in the kidneys significantly increased with Ramipril from systolic 17.2 to 23.8 cm/sec and diastolic 4.2 to 2.0 cm/sec. The addition of Pycnogenol was more effective, improving blood flow from systolic 18.2 to 27.2 and diastolic 4.1 to 9.8 cm/sec.

Only the group taking Pycnogenol was found to have significantly lost weight after six months as compared to baseline, from average BMI 26.5 to 25.0.

"The number of people affected by metabolic syndrome is ever increasing and kidney disease is a growing concern. Pycnogenol cannot compensate for an unhealthy lifestyle, but certainly offers some urgently needed help. Our study suggests that essentially all major characteristics of metabolic syndrome are improved with Pycnogenol as part of a healthier lifestyle." said Dr. Rohdewald.

This preliminary evaluation shows Pycnogenol to offer a natural solution for individuals with metabolic syndrome, particularly for kidney protection. Previous studies have shown Pycnogenol as a supplement to anti-hypertensive medication further improves kidney flow and kidney function. Pycnogenol has also been shown in several studies to lower blood glucose in diabetic patients.


'/>"/>

Contact: Katherine Davis
kdavis@mww.com
312-546-3510
MWW Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Stem cell study could aid motor neurone disease research
2. NIH launches largest oil spill health study
3. University of Maryland School of Medicine study identifies genes associated with binge drinking
4. Compound useful for studying birth defects may also have anti-tumor properties
5. Experts propose global guidelines for safe use of Kava and new Australian study
6. Virginia Tech shares in grant to study effects of climate change on southern pine forests
7. New study shows marine networks can protect fish stocks
8. Rare gene glitch may hold clues for schizophrenia -- NIH-funded study
9. Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome
10. New study illustrates shifting biomes in Alaska
11. NIFA announces grants to study the effects of climate change on agricultural and forest production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... a new model to predict the impact of climate change ... Australia information that could help limit its spread. ... of the British Ecological Society,s journal Functional Ecology , ... and expand the mosquito,s range. But human behaviour in ...
... Institute at Arizona State University associate research scientist Melha Mellata, ... USDA funded project to develop a vaccine against a leading ... APEC is part of a large, diverse group ... They cause a number of complex brain, lung and urinary ...
... January 2009. The Alfred Wegener Institute for Polar ... conduct the ongoing Polarstern expedition LOHAFEX". Independent scientific ... of Education and Research and the Federal Ministry ... concluded that the iron fertilisation experiment LOHAFEX is ...
Cached Biology News:Hoarding rainwater could 'dramatically' expand range of dengue-fever mosquito 2New insights into a leading poultry disease and its risks to human health 2New insights into a leading poultry disease and its risks to human health 3New insights into a leading poultry disease and its risks to human health 4Polarstern expedition 'LOHAFEX' can be conducted 2Polarstern expedition 'LOHAFEX' can be conducted 3
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... ON , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... period ended March 31, 2015.  Biorem,s complete 2015 first quarter financial ... Financial Summary:Three-months ended March 31,(in CDN$,000 except ... , 4,689 , 1,974 Gross profit , ... (318) Net earnings (loss) , 528 , ...
(Date:6/1/2015)... , June 1, 2015  The Val Skinner ... national innovative science curriculum for high school students focused ... 16 th annual LIFE Event (LPGA Pros in ... Ridge Country Club in West Caldwell, N.J. ... LPGA,s biggest stars raised more than $500,000 on Monday, ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Val Skinner Foundation Announces Partnership With Discovery Education 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... 2008, Abbott,s,( NYSE: ABT ) employee giving in the ... number of participating employees and total dollar contributions,despite difficult ... Abbott,employees (74 percent) participated in the company,s employee giving ... contributed more than $12.6,million to non-profit groups in 2008, ...
... Offering , ... Rochester, New York ... innovator in advanced cardiac safety biomakers and automated QT analysis, ... as its quarter over quarter revenues have grown in excess ...
... Belgium and LUND, Sweden, February 23 , ... of Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement ... Brussels: THR) and co-development partner,BioInvent International (OMXS: BINV) announce ... Phase II trial with their long-acting anticoagulant,TB-402 for the ...
Cached Biology Technology:Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 2Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 3iCardiac Reports Significant Revenue Growth and Profitability 2iCardiac Reports Significant Revenue Growth and Profitability 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5
Protein Tyrosine Phosphatase Sampler Kit 10g each...
Zonula Adherens Sampler Kit 10 mu g each...
Golgi Sampler Kit 10g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Biology Products: